http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Ryuichi Iwakiri ) (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Free Paper Session : Basic 2 & Obesity : Intestinal Mucosal Apoptosis By Ghrelin In Fasted Rats
( Jae Myung Park ),( Takashi Kakimoto ),( Tsukasa Kuroki ),( Ryosuke Shiraishi ),( Takehiro Fujise ),( Ryuichi Iwakiri ),( Kazuma Fujimoto ) 대한소화기학회 2007 SIDDS Vol.9 No.-
Background/Aims: Ghrelin is mainly produced in the stomach and has several physiological functions. The aim of this study was to investigate whether ghrelin regulates apoptosis in the small intestinal mucosa of fasted rats. Methods: Intestinal mucosal apoptosis was evaluated as the percentage of fragmented DNA, villus height, TUNEL staining, and western blotting analysis of caspase-3 in 48-h-fasted rats. Crypt cell proliferation was evaluated by counting the number of BrdU-positive cells. Ghrelin was administered intraperitoneally at doses of 2.5, 25, and 250 ㎍/㎏ per 48 h by continuous infusion via an Alzet micro-osmotic pump or injections at 12 h intervals. Ghrelin was also infused in rats that underwent truncal vagotomy. The lowest dose of ghrelin (2.5 ㎍/㎏ per 48 h) was administered into the third cerebroventricle. Results: Ghrelin treatment attenuated the percentage of fragmented DNA in the small intestinal mucosa in 48-h-fasted rats in a dosedependent manner. Both continuous infusion and 12-hourly injections of ghrelin suppressed intestinal apoptosis to almost equal extent, This effect on apoptosis was not attenuated by truncal vagotomy. Cere-broventricular infusion of ghrelin also attenuated intestinal apoptosis. The antiapoptotic effect of ghrelin was confirmed by decreased TUNEL staining, recovery of the villus height, and decreased expression of caspase-3, BrdU uptake indicated that ghrelin enhanced cell proliferation in the intestinal crypt. Conclusions: Taken together, these data indicate that ghrelin enhanced intestinal growth with the suppression of small intestinal mucosal apoptosis in 48-h-fasted rats, suggesting that it controls intestinal function through the regulation of intestinal apoptosis.
-
( Toshifumi Hibi ),( Isao Kamae ),( Philippe Pinton ),( Lyann Ursos ),( Ryuichi Iwakiri ),( Greg Hather ),( Haridarshan Patel ) 대한장연구학회 2021 Intestinal Research Vol.19 No.1
Background/Aims: Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We compared the efficacy of biologics approved in Japan (adalimumab, infliximab, golimumab, and vedolizumab) for treating biologic-naïve patients with UC at their approved doses. Methods: A targeted literature review identified 4 randomized controlled trials of biologics for UC in biologic-naïve Japanese patients. For each study, efficacy outcome data from induction (weeks 6-12) and maintenance (weeks 30-60) treatment were extracted for analysis. Treatment effects on clinical response, clinical remission, and mucosal healing relative to the average placebo results across all trials were estimated using network meta-analyses followed by transformation into probabilities and odds ratios (OR). Results: At the end of induction, the likelihood of clinical response and clinical remission was highest with infliximab (OR: 2.12 and 2.35, respectively) and vedolizumab (OR: 2.10 and 2.32, respectively); the likelihood of mucosal healing was highest with infliximab (OR: 2.24) and adalimumab (OR: 1.86). During maintenance, the likelihood of clinical response and clinical remission was highest with vedolizumab (OR: 6.44 and 4.68, respectively) and golimumab (OR: 5.13 and 3.84, respectively); the likelihood of mucosal healing was significantly higher than placebo with all biologics. Conclu sions: All active treatments were efficacious compared with placebo. Infliximab and vedolizumab had the highest odds for induction of clinical response, remission, and mucosal healing. Golimumab and vedolizumab had numerically higher odds of achieving efficacy outcomes in the maintenance phase. (Intest Res 2021;19:53-61)
-
( Hiroharu Kawakubo ),( Yuichiro Tanaka ),( Nanae Tsuruoka ),( Megumi Hara ),( Koji Yamamoto ),( Hidenori Hidaka ),( Yasuhisa Sakata ),( Ryo Shimoda ),( Ryuichi Iwakiri ),( Motoyasu Kusano ),( Kazuma 대한소화기기능성질환·운동학회 2016 Journal of Neurogastroenterology and Motility (JNM Vol.22 No.2
Background/Aims Upper gastrointestinal symptoms are more frequent and severe in female than in male outpatients in Japan. This study compared the upper gastrointestinal symptoms between healthy male and female young adult volunteers using a questionnaire. Methods In total, 581 third-grade medical students at Saga Medical School aged 22 to 30 years underwent upper gastrointestinal endoscopy and completed a questionnaire (frequency scale for symptoms of gastroesophageal reflux disease) from 2007 to 2013. Of these 581 students, 298 who were negative for Helicobacter pylori infection and had no particular lesions on endoscopic examination were enrolled in the present evaluation. A symptom was defined as positive when the subject evaluated the frequency of the symptom as sometimes, often, or always. Results The subjects comprised of 163 males (average age, 23.7 years) and 135 females (average age, 23.1 years). Upper gastrointestinal symptoms were more frequent in the females (75 of 135, 55.6%) than males (69 of 163, 42.3%; P < 0.05), with a high score for 4 symptoms (bloated stomach, heavy feeling in the stomach after meals, subconscious rubbing of the chest with the hand, and feeling of fullness while eating meals). Of the 144 subjects (69 males and 75 females) who complained of these symptoms, the females complained of dysmotility symptoms more often than did the males, but this was not true for reflux symptoms. Conclusions This study suggests that females develop upper gastrointestinal symptoms more frequently than do males among the young healthy Japanese population. (J Neurogastroenterol Motil 2016;22:248-253)
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
